On April 1, 2021, Eloxx Pharmaceuticals, Inc., acquired Zikani Therapeutics, Inc., pursuant to that certain Agreement and Plan of Merger, dated April 1, 2021, by and among Eloxx, Delta Merger Sub Acquisition Corporation, a Delaware corporation and direct, wholly owned subsidiary of the Company (“Merger Sub”), and Zikani. Effective as of the effective time of the Merger on April 1, 2021, the Company appointed Daniel Geffken to serve as the Company’s Interim Chief Financial Officer. Mr. Geffken provides services through Danforth Advisors, LLC. It is contemplated that Danforth Advisors and the Company will enter into a new consulting agreement after the effective time of the Merger (the “Consulting Agreement”) concerning services to be provided by Danforth Advisors for the benefit of the Company, including those services provided by Mr. Geffken. Mr. Geffken previously provided services as the Chief Financial Officer of Zikani through Danforth Advisors.